Efficacy and safety of COVID-19 vaccines

Cochrane library, Год журнала: 2022, Номер 2023(3)

Опубликована: Дек. 7, 2022

Язык: Английский

---

Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

The Lancet Microbe, Год журнала: 2023, Номер 4(4), С. e236 - e246

Опубликована: Фев. 28, 2023

Summary

Background

The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness and death is uncertain due to the rarity data individual trials. How well antibody concentrations can predict also uncertain. We aimed assess these infections different severities dose–response relationship between efficacy.

Methods

did a systematic review meta-analysis randomised controlled trials (RCTs). searched PubMed, Embase, Scopus, Web Science, Cochrane Library, WHO, bioRxiv, medRxiv for papers published Jan 1, 2020 Sep 12, 2022. RCTs on were eligible. Risk bias was assessed using tool. A frequentist, random-effects model used combine common outcomes (ie, symptomatic asymptomatic infections) Bayesian rare hospital admission, infection, death). Potential sources heterogeneity investigated. relationships neutralising, spike-specific IgG receptor binding domain-specific titres with examined by meta-regression. This registered PROSPERO, CRD42021287238.

Findings

28 (n=286 915 vaccination groups n=233 236 placebo groups; median follow-up 1–6 months after last vaccination) across 32 publications included this review. combined full 44·5% (95% CI 27·8–57·4) infections, 76·5% (69·8–81·7) 95·4% credible interval 88·0–98·7) hospitalisation, 90·8% (85·5–95·1) 85·8% (68·7–94·6) death. There against but insufficient evidence suggest whether could differ according type vaccine, age vaccinated individual, between-dose (p>0·05 all). Vaccine infection waned over time vaccination, an average decrease 13·6% 5·5–22·3; p=0·0007) per month be enhanced booster. found significant non-linear each (p<0·0001 all), there remained considerable efficacy, which cannot explained concentrations. risk low most studies.

Interpretation

higher than milder infection. wanes Higher are associated estimates precise predictions difficult large unexplained heterogeneity. These findings provide important knowledge base interpretation application future studies issues.

Funding

Shenzhen Science Technology Programs.

Язык: Английский

---

An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines

Progress in Biophysics and Molecular Biology, Год журнала: 2023, Номер 178, С. 32 - 49

Опубликована: Фев. 20, 2023

Язык: Английский

---

The role of vaccines in the COVID-19 pandemic: what have we learned?

Seminars in Immunopathology, Год журнала: 2023, Номер 45(4-6), С. 451 - 468

Опубликована: Июль 12, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and caused the disease (COVID-19) pandemic that has so far claimed approximately 20 million lives. Vaccines were developed quickly, became available end of 2020, had a tremendous impact on protection from SARS-CoV-2 mortality but with emerging variants morbidity was diminished. Here I review what we learned COVID-19 vaccinologist's perspective.

Язык: Английский

---

Evaluation of effectiveness and safety of Subolesin anti-tick vaccine in Ugandan multi-site field trial

npj Vaccines, Год журнала: 2024, Номер 9(1)

Опубликована: Сен. 18, 2024

Язык: Английский

---

Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction

Virology, Год журнала: 2025, Номер 604, С. 110394 - 110394

Опубликована: Янв. 11, 2025

Язык: Английский

---

Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine

JAMA Network Open, Год журнала: 2023, Номер 6(5), С. e2310302 - e2310302

Опубликована: Май 3, 2023

Importance The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A Plus) showed good safety immunogenicity in phase 1 2 trials, but the clinical efficacy of vaccine remains unknown. Objective To evaluate a 2-dose regimen (cohort 1) 3-dose with 2) Iranian adults. Design, Setting, Participants A multicenter, randomized, double-blind, placebo-controlled, 3 trial was conducted at 6 cities cohort 2. included individuals aged 18 to 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recent immunoglobulin immunosuppressive therapy, presentation laboratory-confirmed COVID-19 on enrollment. study from April 26 September 25, 2021. Interventions In 1, doses (n = 13 857) placebo 3462) were administered 28 days apart. 2, plus dose 4340) 1081) Vaccinations via intramuscular injection. Main Outcomes Measures primary outcome polymerase chain reaction–confirmed symptomatic infection least 14 after vaccination completion. Other outcomes adverse events severe COVID-19. Intention-to-treat analysis performed. Results total 17 319 received 5521 placebo. Cohort comprised 60.1% men group 59.1% group; 59.8% 59.9% group. mean (SD) age 39.3 (11.9) 39.7 (12.0) no significant difference between groups. median follow-up time 100 (IQR, 96-106) and, 142 (137-148) days. 461 (3.2%) cases occurred 221 (6.1%) (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) 51 (4.3%) 64.9%; 49.7%-59.5%). incidence serious lower than 0.1%, vaccine-related deaths. Conclusions Relevance this FINLAY-FR-1A, third acceptable against as well COVID-19–related infections. Vaccination generally safe tolerated. Therefore, Soberana may have utility an option for mass population, especially resource-limited settings, because its storage condition affordable price. Trial Registration isrctn.org Identifier: IRCT20210303050558N1

Язык: Английский

---

PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals

Scientific Reports, Год журнала: 2023, Номер 13(1)

Опубликована: Май 18, 2023

The optimal booster vaccine schedule against COVID-19 is still being explored. present study aimed at assessment of the immunogenicity and antibody persistency inactivated-virus based vaccine, BBIP-CorV protein-subunit vaccines, PastoCovac/Plus through heterologous homologous prime-boost vaccination. Totally, 214 individuals who were previously primed with BBIBP-CorV vaccines divided into three arms on their choice as regimens BBIBP-CorV/PastoCovac (n = 68), Plus 72) 74). PastoCovac recipients achieved highest rate anti-Spike IgG titer rise a fourfold in 50% group. Anti-RBD neutralizing mean fold almost similar between receivers. durability results indicated that generated antibodies persistent until day 180 all groups. Nevertheless, higher was seen regimen compared to Furthermore, no serious adverse event recorded. protein subunit-based led stronger humoral immune response comparison Both subunit boosters neutralized SARS-CoV-2 significantly more than BBIP-CorV. Notably, could be successfully applied convenient safety profile.

Язык: Английский

---

CHO cells for virus-like particle and subunit vaccine manufacturing

Vaccine, Год журнала: 2024, Номер 42(10), С. 2530 - 2542

Опубликована: Март 19, 2024

Chinese Hamster Ovary (CHO) cells, employed primarily for manufacturing monoclonal antibodies and other recombinant protein (r-protein) therapeutics, are emerging as a promising host vaccine antigen production. This is exemplified by the recently approved CHO cell-derived subunit vaccines (SUV) against respiratory syncytial virus (RSV) varicella-zoster (VZV), well enveloped virus-like particle (eVLP) hepatitis B (HBV). Here, we summarize design, production, immunogenicity features of these review most recent progress CHO-derived in pre-clinical clinical development. We also discuss challenges associated with production focus on ensuring viral clearance eVLP products.

Язык: Английский

---

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

mSystems, Год журнала: 2023, Номер 8(2)

Опубликована: Март 2, 2023

Over the past 150 years, vaccines have revolutionized relationship between people and disease. During COVID-19 pandemic, technologies such as mRNA received attention due to their novelty successes. However, more traditional vaccine development platforms also yielded important tools in worldwide fight against SARS-CoV-2 virus. A variety of approaches been used develop that are now authorized for use countries around world. In this review, we highlight strategies focus on viral capsid outwards, rather than nucleic acids inside. These fall into two broad categories: whole-virus subunit vaccines. Whole-virus virus itself, either an inactivated or attenuated state. Subunit contain instead isolated, immunogenic component Here, candidates apply these different ways. a companion manuscript, review recent novel nucleic-acid based technologies. We further consider role programs played prophylaxis at global scale. Well-established proved especially making accessible low- middle-income countries. Vaccine established undertaken much wider range those using nucleic-acid-based technologies, which led by wealthy Western Therefore, platforms, though less from biotechnological standpoint, proven be extremely management SARS-CoV-2.

Язык: Английский

---